The care is based on the administration of an anti-leukemic polychemotherapy, using several anti-cancer treatments. For a few years, new immunotherapy drugs complement conventional chemotherapy.

Certain forms of AML, at high risk of relapse, require an allogenic  hematopoietic stem cells transplantation (HSCT), often called “Bone Marrow Transplant”. This treatment is only possible under the following conditions:

  • the disease is controlled, in so-called “complete remission”
  • the patient is in physical and psychological capacity to receive HSCT
  • the patient has a bone marrow donor (related or unrelated donor)

HSCT is also sometimes indicated in case of AML relapse.

HSCT remains a heavy treatment, which can cause long-term sequelae.  Patients should be followed in order to detect potential sequelae as soon as possible and manage them quickly to reduce their long-term impact.

Children and adolescents newly diagnosed with AML are currently treated according to the international protocol MyeChild01. For more information, you can consult the information sheet on the U-LINK website.

CONECT-AML is a biological, ancillary project, that is to say associated with the MyeChild01 protocol, which will be systematically proposed by the patient’s referring physician.

Many treatments are under development. In certain situations of refractory disease or relapse, physicians could propose them. The list of open clinical trials is available on the U-LINK website.